ArticleInternational journal of molecular sciences2021
A Novel L-Asparaginase from Hyperthermophilic Archaeon
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Hyperthermophilic L-Asparaginase fromInternational journal of molecular sciences · 2025Article
- A Novel Approach for the Activity Assessment of L-Asparaginase Formulations When Dealing with Complex Biological Samples.International journal of molecular sciences · 2025Article
- Potential of Hyperthermophilic L-Asparaginase fromFoods (Basel, Switzerland) · 2025Article
- Recovery of nearly 3,000 archaeal genomes from 152 terrestrial geothermal spring metagenomes.Scientific data · 2025Article
- Production Process Optimization of RecombinantACS omega · 2024Article
- L-Asparaginase Conjugates from the Hyperthermophilic ArchaeaInternational journal of molecular sciences · 2024Article
- Desirable L-asparaginases for treating cancer and current research trends.Frontiers in microbiology · 2024Review
- Thermal Stability Enhancement of L-Asparaginase fromFoods (Basel, Switzerland) · 2023Article
- Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production.International journal of molecular sciences · 2023Review
- Enhancing the Catalytic Activity of Thermo-Asparaginase fromInternational journal of molecular sciences · 2023Article
- Achievement of the Selectivity of Cytotoxic Agents against Cancer Cells by Creation of Combined Formulation with Terpenoid Adjuvants as Prospects to Overcome Multidrug Resistance.International journal of molecular sciences · 2023Article
- Thermo-L-Asparaginases: From the Role in the Viability of Thermophiles and Hyperthermophiles at High Temperatures to a Molecular Understanding of Their Thermoactivity and Thermostability.International journal of molecular sciences · 2023Review
- Improvement of Biocatalytic Properties and Cytotoxic Activity of L-Asparaginase fromPharmaceuticals (Basel, Switzerland) · 2022Article
- Molecular Analysis of L-Asparaginases for Clarification of the Mechanism of Action and Optimization of Pharmacological Functions.Pharmaceutics · 2022Review
- Highly Active Thermophilic L-Asparaginase fromInternational journal of molecular sciences · 2021Article
- Characterization and Evaluation of the Anti-proliferative Activity and Hypersensitivity of L-Asparaginase fromAvicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
L-asparaginase (L-ASNase) is a vital enzyme with a broad range of applications in medicine and food industry. Drawbacks of current commercial L-ASNases stimulate the search for better-producing sources of the enzyme, and extremophiles are especially attractive in this view. In this study, a novel L-asparaginase originating from the hyperthermophilic archaeon
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.